May 27, 2014

The May/June 2014 Skin & Itch Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of AmLactin Cerapeutic Restoring, Cetaphil RestoraDerm Skin Restoring, Olay Advanced Healing Intensive, Curél Intesive Healing, Nivea Extended Moisture, Aveeno 1% Hydrocortisone Anti-itch, Extra Strength Benadryl Itch Stopping and Corizone 10 Anti-itch Ultra Moisturing Creme Plus.

May 22, 2014

Prasco Labs on Thursday announced it has entered into a distribution and supply agreement with Recordati Rare Diseases for the rights to distribute ibuprofen lysine injection, the authorized generic version of NeoProfen (ibuprofen lysine).

May 22, 2014

Publix Pharmacy on Thursday announced it will offer free 30-day supplies of amlodipine to customers with a prescription for the medication.

May 16, 2014

The Food and Drug Administration on Thursday announced it required Sunovion Pharmaceuticals, manufacturer of the sleep drug Lunesta (eszopiclone), to change the drug label and lower the current recommended starting dose.

May 15, 2014

Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.

May 14, 2014

Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).

May 14, 2014

Mylan on Wednesday announced that it has launched olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths. The drug is the generic version of Zyprexa Zydis tablets from Eli Lilly and Co.

May 13, 2014

Valeant Pharmaceuticals on Monday announced that certain of its subsidiaries have entered into settlement agreements with Actavis related to Actavis' generic versions of Tiazac XC.

May 9, 2014

Ajanta Pharma USA on Friday announced the launch of risperidone tablets (0.25-mg, 0.5-mg, 1-mg, 2-mg, 3-mg and 4-mg), the generic version of Risperdal.

May 9, 2014

Bayer agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion. The OTC acquisition will give Bayer the global No. 2 position in nonprescription products following recently announced consolidations in this growing healthcare industry segment, and will significantly enhance Bayer’s business across multiple therapeutic categories and geographies. Merck's consumer care business includes such leading brands as Claritin, Coppertone and Dr. Scholl’s. Pro forma sales of the combined businesses in 2013 amounted to $7.4 billion with Merck’s business contributing approximately $2.2 billion.

Upon completion of the acquisition, Bayer is expected to achieve global leadership positions in dermatology and gastrointestinals and advance to the No. 2 position in the cold, allergy, sinus and flu category. Bayer will remain No. 2 in nutritionals and No. 3 in analgesics. Overall, the proposed GlaxoSmithKline-Novartis combination represents the largest consumer health business with about 5.7% share, according to reports. The Bayer/Merck combination comes in second with around 4.5% share. McNeil Consumer rounds out the top three globally with a share just above 4%.

May 9, 2014

One thing remains unchanged about our nurse practitioner and physician assistant readers: Retail clinicians tend to love their jobs.

May 9, 2014

CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis.

May 6, 2014

Axium Healthcare Pharmacy on Tuesday announced that it has been accepted into the GlaxoSmithKline Oncology network.

May 6, 2014

In a related transaction to Tuesday morning's acquisition of Merck's OTC portfolio, Bayer also agreed to enter into a strategic pharma collaboration in the area of cardiovascular diseases with a focus on sGC modulation.

May 6, 2014

Pfizer's Nexium 24HR will launch May 27, Pfizer reported in a conference call Monday.

May 1, 2014

Purdue Pharma on Wednesday announced that it filed a new drug application with the Food and Drug Administration to market a hydrocodone bitartrate tablet, which is formulated to incorporate abuse-deterrent technology.

April 30, 2014

The Food and Drug Administration on Tuesday granted approval to Zykadia (ceritinib) for patients with a specific type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

April 29, 2014

Jubilant Life Sciences, an integrated pharmaceuticals and life sciences company, last week announced that it received approval from the Food and Drug Administration for spironolactone tablets, 25 mg, 50 mg and 100 mg, which is the generic version of Aldactone.

April 28, 2014

Sandoz on Monday announced the introduction of its adapalene 0.3% gel, a generic version of Differin gel, 0.3% from Galderma Labs.

April 23, 2014

Dr. Reddy's Labs on Wednesday announced the launch of fenofibrate capsules, USP in 43-mg and 130-mg strengths. The drug is the generic version of Antara (fenofibrate) capsules.

April 21, 2014

McNeil Consumer Healthcare recently introduced a new form to the Zyrtec portfolio of allergy-relief products — an oral, dissolvable tablet.

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

April 15, 2014

Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products.

April 15, 2014

Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form.